The agreements provide for $192.5 million in payments over about 5 years, including up to $55 million tied to records delivered. A temporary limit on licensing some brain data to others restricts Tempus's sales options.
The fixed cancer-data payments give Tempus cash across the agreement term, billed each quarter. Some brain-data fees depend on records delivered, and Tempus cannot offer those records to other buyers for a set period.
Bristol Myers gets access to more cancer and brain data for drug development, but pays for that access. The filing reports no resulting change in products or sales, so it does not change the company's outlook.
Follow Tempus AI, Inc. (TEM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEM